---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-007026"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:19:03.652105+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Neoleukin initiates strategic alternatives review, cuts workforce by 70%, CEO Drachman to step down

## Summary
- Engaged SVB Securities to explore sale, merger, asset divestiture, licensing, or other transaction to maximize shareholder value.
- Board approved 70% workforce reduction to preserve cash; completion expected in first half of 2023.
- CEO Jonathan Drachman, M.D., stepping down after a short transition period.
- No assurance that any transaction will occur or on attractive terms; company will not disclose updates until definitive agreements reached.

## SEC filing metadata
- accession: 0001628280-23-007026
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000162828023007026/0001628280-23-007026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000162828023007026/nltx-20230308.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-007026
- JSON: https://secwatch.observer/filing/0001628280-23-007026.json
- Plain text: https://secwatch.observer/filing/0001628280-23-007026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.